Exploring the extremes of coronary artery disease
Official title: Extremes of Coronary Artery Disease and Normality: Understanding Novel Causative and Protective Factors in the Development of Coronary Artery Disease (CAD Extremes)
Run by National Heart Centre Singapore · NCT05775445 · Data updated 2026-11-12
This study is trying to find out why some people with coronary artery disease have serious issues despite not having common risk factors, while others with many risk factors have little to no disease, by looking at their genes and blood samples.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 21 Years to 99 Years |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | National Heart Centre Singapore Academic / other |
| Locations | 1 site (Singapore) |
| Status | Recruiting |
| Started | May 30, 2023 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | February 21, 2024 |
| Trial ID | NCT05775445 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include young adults with significant CAD but no traditional risk factors, as well as older patients with significant CAD and established risk factors.
✕Probably not a fit
Patients with well-established coronary artery disease and multiple risk factors who do not fit the extreme profiles may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates two distinct groups of patients with coronary artery disease (CAD): those who have significant CAD despite low risk factors and those with multiple risk factors but little to no CAD. The researchers aim to identify molecular markers that may contribute to or protect against acute coronary syndrome (ACS) by analyzing genetic, blood, and atherosclerotic samples from these extreme patient groups. Utilizing single-cell RNA sequencing and a multi-omics approach, the study seeks to uncover insights into the mechanisms underlying these contrasting phenotypes. The findings could enhance understanding of CAD and inform future therapeutic strategies.
Why it matters
Potential benefit: If successful, this study could lead to the identification of new biomarkers for coronary artery disease, improving risk assessment and treatment strategies for patients.
How similar studies have gone: While the study's approach is innovative, previous research has explored similar themes in understanding CAD, though this specific focus on extreme phenotypes is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Group 1: 1. Evidence of significant CAD a. Coronary angiogram or CT coronary angiogram with documented stenosis \>=50% in left main or \>=70% in major epicardial vessel or major branches (LAD, LCX, RCA) AND all of the following 2. Age \</= 45 for males and \</= 50 for females 3. Absence of diabetes mellitus 4. Absence of tobacco use 5. No prior CVA or PAD Group 2 1. Evidence of significant CAD 1. Coronary angiogram or CT coronary angiogram with documented stenosis \>=50% in left main or \>=70% in major epicardial vessel or major branches (LAD, LCX, RCA) AND all of the following 2. Age \</= 45 for males and \</= 50 for females 3. Absence of diabetes mellitus 4. Absence of tobacco use 5. No prior CVA or PAD Group 3 1. Evidence of significant CAD with one of the following: 1. age\>65 2. Diabetes mellitus 3. End Stage Renal Failure (ESRF) 4. Framingham risk score \>10% Group 4 1\. No evidence of significant CAD and all of the following 1. Age \<55 for males, \<65 for females 2. Absence of diabetes mellitus 3. Absence of CKD 4. Absence of tobacco use Exclusion Criteria: 1. Prior history of cancer (excludes pre-cancerous lesions) 2. Expected life expectancy less than 1 year 3. Known autoimmune disease 4. Psychiatric illness 5. Chronic lung disease requiring long term medications or oxygen 6. Chronic infective disease, including tuberculosis, hepatitis B and C; and HIV 7. Inability to comply with study protocol 8. Any other acute or chronic medical or physical condition deemed by the investigator to affect study outcomes
Where it's running
-
National Heart Centre Singapore
Singapore, Singapore Recruiting
Study contacts
- Principal investigator: Khyung Keong Yeo — National Heart Centre
- Study coordinator: Aishah Toh
- Email: aishah.toh@nhcs.com.sg
- Phone: 67042282
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
-
Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance
This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.
-
Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in CABG Patients
This study tests whether the amount a patient’s pulse pressure varies during surgery relates to how quickly lactate levels drop after CABG.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.